{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-076471","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.375788+00:00","generated_at":"2026-06-04T08:33:30.181459+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Equillium reports $40.9M cash; EQ101 Phase 2 topline due Q2; Ono itolizumab option decision 2H 2024","bullets":["Cash $40.9M at Dec 31, 2023; runway into 2H 2025.","EQ101 Phase 2 alopecia areata enrollment complete; topline data Q2 2024.","FY2023 revenue $36.1M (Ono partnership); net loss $13.3M vs $62.4M prior year.","Ono option exercise for itolizumab expected 2H 2024; $33M exercise payment plus $101M milestones.","Phase 3 EQUATOR aGVHD interim review expected Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-076471","json":"https://secwatch.observer/filing/0001193125-24-076471.json","markdown":"https://secwatch.observer/filing/0001193125-24-076471.md","text":"https://secwatch.observer/filing/0001193125-24-076471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524076471/0001193125-24-076471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524076471/d813838d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:33:30.181459+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7a54aeb233e37c5635c902890ebad7607fb82c0","claim":"Equillium, Inc. reported the fourth quarter and full year 2023 results: revenue $9.2 million.","evidence_excerpt":"Revenue for the fourth quarter of 2023 was $9.2 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746466/000119312524076471/0001193125-24-076471-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Revenue","value":"$9.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}